Manufactured antibodies are laboratory-made versions of antibodies, also known as monoclonal antibodies. In theory, they can be injected into patients to speed COVID-19 recovery, or to prevent infection from taking hold. In a small new study published in the journal Nature, researchers found new types of monoclonal antibodies that are particularly potent against the SARS-CoV-2 virus that causes COVID-19. They found that these monoclonal antibodies can attack the virus in new ways.
In a webinar last month, Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases (NIAID), said that monoclonal antibodies are “almost a sure bet” in fighting COVID-19.
Researchers Found Antibodies Can Treat COVID-19 In New Ways
For the study, researchers from Columbia University isolated 61 antibodies from five critically ill patients who were infected with SARS-CoV-2, the virus that causes COVID-19. Of those antibodies, 19 “potently neutralized” the virus in a lab. The researchers created monoclonal antibodies to mimic these natural antibodies and tested them in hamsters.
The researchers found that monoclonal antibodies were split into two groups: those that target the area of the virus’s crown-like spikes known to attach to human cells, and those that target a previously unexplored region of the spikes.
“These findings show which sites on the viral spike are most vulnerable,” David Ho, MD, professor of medicine at Columbia University and the study director, said in a statement. “Using a cocktail of different antibodies that are directed to different sites in spike will help prevent the virus becoming resistant to the treatment.”
This isn’t the only study on monoclonal antibodies to treat COVID-19. On August 10, the National Institutes of Health (NIH) announced recruitment for two Phase 3 randomized, placebo-controlled, double-blind clinical trials to test whether experimental monoclonal antibodies can prevent COVID-19 infection.
“These are not difficult to produce and our bodies can’t tell the difference between monoclonal antibodies and ones our bodies naturally make,” Sanjay Sethi, MD, professor and chief of pulmonary, critical care, and sleep medicine at the University at Buffalo, tells Verywell. While Seth was not involved with the study, he has researched monoclonal antibodies. “If this works, it will be a great thing.”
How Monoclonal Antibodies Work
Just like natural antibodies, monoclonal antibodies bind directly to portions of viruses and keep them from infecting a person, Sethi says, adding they may “speed up recovery” in patients who are already sick.
Monoclonal antibodies may also provide short-term protection from SARS-CoV-2 and “could serve as important components of the COVID-19 pandemic response until vaccines become available,” the NIH says.
Monoclonal antibodies are typically given as an injection. It’s unclear at this point how often someone would need to be treated with monoclonal antibodies for them to work against COVID-19, because they wouldn’t last as long as antibodies produced naturally by the body’s immune system.
“These are trials—we just don’t know for sure yet,” Sethi says.
According to Rajeev S. Fernando, MD, an infectious disease specialist at Stony Brook Southampton Hospital in New York, monoclonal antibodies could be more of a supplemental treatment.
“I’m not sure it’s a game-changer itself in treatment for critically ill patients, but, in those patients, I would probably use it in conjunction with remdesivir and dexamethasone at this time, as much is unknown,” he tells Verywell.
Monoclonal Antibodies Have Been Used Before
While developing antibodies for COVID-19 requires innovative research, monoclonal antibodies have long been used in medicine.
“We have been using manufactured antibodies for a while now for things like cancer, rheumatoid arthritis, and inflammatory bowel disease,” Jamie K. Alan, PhD, associate professor of pharmacology and toxicology at Michigan State University, tells Verywell. She cites the chemotherapy drug trastuzumab (Herceptin) and arthritis medication adalimumab (Humira) as popular monoclonal antibody treatments.
Monoclonal antibodies have also been used to treat Ebola. Research shows that ZMapp, a combination of three monoclonal antibodies, can prevent people from dying of the virus.
“Monoclonal antibodies are already changing how we think about Ebola,” Amesh A. Adalja, MD, senior scholar at the Johns Hopkins Center for Health Security, tells Verywell. “It’s changed the virus to a treatable illness.”
Monoclonal Antibodies Have Some Drawbacks
It’s “impossible to predict” right now what, if any, side effects using manufactured antibodies to treat or prevent COVID-19 may cause, Alan says. But, in general with monoclonal antibody therapies, she says people may experience side effects like:
ItchingBurningSwelling at the injection site
Cost is a potential hurdle with this form of treatment, according to Fernando.
“Monoclonal antibodies are super expensive, so I’m not sure how it will be provided to the general public if these trials are successful,” he says.
The information in this article is current as of the date listed, which means newer information may be available when you read this. For the most recent updates on COVID-19, visit our coronavirus news page.
